Form 4: Apellis General Counsel Sells Shares for Tax Withholding

Apellis Pharmaceuticals' General Counsel, David O. Watson, sold 7,832 shares of common stock to cover tax withholding obligations related to RSU release.

Summary

• David O. Watson, General Counsel and an Officer of Apellis Pharmaceuticals, Inc. (APLS), reported a transaction on January 22, 2026.
• The transaction involved the sale of 7,832 shares of Apellis Pharmaceuticals Common Stock.
• The shares were sold at a price of $21.7654 per share.
• The purpose of the sale was to cover tax withholding on Restricted Stock Units (RSUs) that were released on January 21, 2026.
• Following this transaction, David O. Watson directly beneficially owns 88,531 shares of Common Stock.
• Indirect beneficial ownership includes 10,000 shares in a custodial account for minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023.
• The Watson Education Trust holds 0 shares, and beneficial ownership is disclaimed over shares held by the trusts except to the extent of pecuniary interest.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction for tax purposes, which is neutral in sentiment and does not reflect positively or negatively on the company's operational or financial performance.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This is a routine insider transaction common in publicly traded companies, particularly in the biotech and pharmaceutical sectors, where executives often receive compensation in the form of Restricted Stock Units (RSUs). The sale of shares to cover tax withholding upon RSU vesting is a standard practice and does not typically indicate a change in the company's fundamental outlook or the executive's confidence in the company.

Related Party Transactions

• Indirect beneficial ownership includes 10,000 shares in a custodial account for minor children of the reporting person.
• Indirect beneficial ownership includes 50,136 shares held by The David O. Watson Irrevocable Trust of 2023, for which the reporting person disclaims beneficial ownership except for pecuniary interest.
• The Watson Education Trust holds 0 shares, and the reporting person disclaims beneficial ownership except for pecuniary interest.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, tax-related insider sale and does not signal a change in company fundamentals or management's long-term view.
• Employees: No direct impact indicated by this filing.

Key Dates

Recommendation

The filing details a routine insider stock sale to cover tax obligations upon RSU vesting. This type of transaction is common and does not provide new fundamental information that would warrant a change in an investment thesis or a 'buy' or 'sell' recommendation. Therefore, a 'hold' recommendation is appropriate as there is no new material information to alter current positions.

Keywords

Apellis Pharmaceuticals, APLS, Form 4, Insider Transaction, Stock Sale, Tax Withholding, RSU Vesting, General Counsel